Work

Final results of a phase 2 study of ramucirumab (RAM) plus eribulin (E) versus E in advanced metastatic breast cancer (MBC).

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.1035

Authors: Denise A. Yardley, Paul D. Richards, James Andrew Reeves, Elizabeth Claire Dees, Cynthia R. C. Osborne, Hatem Hussein Soliman, Devchand Paul, Foluso Olabisi Ademuyiwa, Troy H. Guthrie, Jane L. Bromund, Yihuan Xu, Ayman B. Ibrahim

Institutions: Sarah Cannon, Tennessee Oncology, Florida Cancer Specialists & Research Institute, UNC Lineberger Comprehensive Cancer Center, Baylor University Medical Center, Moffitt Cancer Center, Rocky Mountain Cancer Centers, Washington University in St. Louis, Baptist Cancer Center, Eli Lilly (United States)

Language: English

Topic: Cancer Treatment and Pharmacology

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2602803086

Cites:

Cited by: 16

Related to: 10